Drugs / DT2216
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06964009 | Sep 2025 → Dec 2026 expected | ovarian carcinoma | Elizabeth Stover, MD, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT04886622 | Aug 2021 → Jun 2024 | cancer, hematopoietic and lymphoid cell neoplasm | Dialectic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06620302 | Jun 2025 → Dec 2031 expected | childhood malignant neoplasm, fibrolamellar hepatocellular carcinoma | Children's Oncology Group | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT2216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04886622 ↗ |
| Action | Inhibit | “It may stop the growth of tumor cells by blocking Bcl-xL” NCT06620302 ↗ |
| Modality | Other / unclassified | “Bcl-xL proteolysis targeting chimera DT2216” NCT06620302 ↗ |
| Route | Intravenous | “0.04 to 0.4mg/kg IV twice weekly (BIW)” PMID 41225624 ↗ Nov 2025 |
| Target | BCL2L1 | “DT2216 was more effective than navitoclax and reduced platelet toxicity in preclinical models by selectively degrading BCL-XL via the VHL E3 ligase, which is minimally...” PMID 41225624 ↗ Nov 2025 |